MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$9,552K
EPS
-$0.16
Unit: Thousand (K) dollars
Income Statement
2026-06-30
2025-12-31
2025-09-30
Total revenues
0
41,297
5,442
Research and development
3,434
5,592
8,597
General and administrative
6,492
4,300
4,174
Impairment of long-term asset
-
0
587
Severance and other employee costs
-
0
-
Restructuring
0
0
0
Total operating expenses
9,926
9,892
13,358
Loss from operations
-9,926
31,405
-7,916
Interest income
377
1,243*
532
Other income (expense), net
-3
-2*
2
Total other income, net
374
1,241
534
Net income (loss) before income taxes
-
32,646*
-7,382
Income tax expense
-
261*
0
Net loss and comprehensive loss
-9,552
32,385
-7,382
Basic EPS
-0.16
0.574
-0.13
Diluted EPS
-0.16
0.473
-0.13
Basic Average Shares
57,968,608
56,397,653
56,280,844
Diluted Average Shares
57,968,608
68,473,101
56,280,844
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Interest income$377K (-49.05%↓ Y/Y)Net loss andcomprehensive loss-$9,552K (-461.88%↓ Y/Y)Total other income,net$374K (-49.73%↓ Y/Y)Other income(expense), net-$3K (-175.00%↓ Y/Y)Loss from operations-$9,926K (-306.14%↓ Y/Y)Total operatingexpenses$9,926K (-40.32%↓ Y/Y)General andadministrative$6,492K (10.45%↑ Y/Y)Research and development$3,434K (-67.82%↓ Y/Y)

Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics, Inc. (SPRO)